Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
347
resultados
Última actualización
27/07/2026 [09:40:00]
Resultados 175 a 200 de 347
Resumen de: EP4764499A1
0001 The present invention relates to a method of detection of glycated proteins, particularly gHSA, which comprises the steps of: i) providing anthracene boronic acid methacrylate (ABAM): 10-N-methyl-N-(o-boronobenzyl)aminomethyl-anthracene-9-methyl methacrylate; ii) preparing a solution of ABAM in a biocompatible buffer with pH in the range of from 6.5 to 8.5 or in in vitro blood plasma sample of a healthy subject; iii) measuring initial fluorescence intensity of ABAM solution from step ii) at the wavelength of from 410 to 520 nm; iv) in vitro mixing of a known amount of ABAM solution from step ii) with a known amount of biological sample; v) measuring fluorescence intensity of the mixture from step iv) at the wavelength of from 410 to 520 nm; vi) determining the fluorescence intensity increases between the initial control fluorescence intensity measured in step iii) and the fluorescence intensity of the mixture of ABAM and biological sample measured in step v); vii) calculating the amount of glycated proteins in the biological sample. 0002 The present invention further relates to the use of this method in determination of the total concentrations of glycated proteins, particularly gHSA, in plasma samples and diagnostics for diabetes mellitus.
Resumen de: EP4763997A1
The present invention relates to biomarkers capable of diagnosing various brain and nervous system diseases, and a method of providing information for diagnosing brain and nervous system diseases using the same. According to the present invention, it is possible to diagnose, at an early stage, the onset of a brain and nervous system disease or the likelihood of developing the disease or diagnose the progress or prognosis of the disease or the therapeutic effect against the disease, by measuring the expression level of the biomarker protein of the present invention or a gene encoding the same in the aqueous humor of the eye.
Resumen de: WO2025040574A1
Alzheimer's disease is strongly linked to biological aging and bioenergetic abnormalities. Systemic dysregulation of metabolism is a hallmark of the physiological decline of tissues with age. We aimed to explore untargeted metabolomic profiling of blood samples from amyloid-positive people to distinguish individuals who progressed to cognitive decline from those who remained cognitively intact despite having amyloid deposits in the brain. A minimal signature of 9 metabolites identified decliners and non-decliners of cognitive function in participants with an amyloid load. These findings are of clinical importance as they suggest that a metabolic fingerprint may help to predict patients who will develop cognitive decline. Due to the high prevalence of brain amyloid-positivity in older adults, identifying adults who will have cognitive decline will enable the development of personalized and early interventions. The present invention relates to an in vitro method for predicting cognitive decline in a subject comprising the step of determining the level of at least one metabolite selected in the group consisting of 3-hydroxybutyrate, acetone, triglyceride 48:3, glucose, citrate, succinate, methionine, serine, sphingomyelin d18:1/C26:0 in a biological sample obtained from the subject.
Resumen de: CN122256501A
0001 本发明涉及生物医药领域，具体涉及偏头痛诊断的生物标志物、试剂盒及其应用。本发明所述的偏头痛疾病相关的生物标志物包括COL4A2，同时还包括MMP‑14、LCAT、ADAMTS13和CPXM2中的任意一种或多种的组合。本发明基于临床健康对照和偏头痛患者的蛋白质组学数据，应用生信分析和机器学习等方法，深入挖掘对偏头痛疾病诊断最有预警价值的蛋白质组合，并在扩大样本的临床队列中进行验证，为新发现的生物标志物的临床转化提供良好前景，同时也为后续机制研究奠定基础。
Resumen de: CN122255284A
本发明涉及生物技术领域，具体的，本发明公开了一种酪氨酸碘化修饰PP2A蛋白的单克隆抗体、制备方法及应用。本发明通过制备酪氨酸碘化修饰的PP2A蛋白抗原肽，免疫兔制备单克隆抗体，并利用噬菌体展示技术淘选、表达载体扩增和ELISA筛选，最终获得一株能有效识别靶标的单克隆抗体R004。该抗体在免疫组织化学、细胞免疫荧光和蛋白免疫印迹中均表现出良好的灵敏度和特异性。本发明筛选得到的单克隆抗体可以用于PP2A蛋白催化亚基307位酪氨酸碘化修饰的检测中，为肿瘤诊断、抗肿瘤和神经疾病药物的研发提供支持。
Resumen de: WO2020168254A1
A method of determining the potency of an immune cell is described. The method includes the steps of contacting an immune cell with an effective amount of a cell exosome and detecting the amount of a cytokine produced by the immune cell. Kits for assaying immune cell potency are also described. Potency assays are important for satisfying the FDA requirements for new biological agents, such as immunotherapeutic cells. Methods of using potent immune cells as an immunotherapeutic treatment are described.
Resumen de: WO2024235880A1
The invention relates to an in vitro method for diagnosing or predicting a neurodegenerative disease in a subject, said method comprising A/T/N classification in nasal secretion samples obtained from said subject. Said A/T/N classification subsequently may be used, but is not limited to, the diagnosis of Alzheimer's disease (AD), the diagnosis of SNAP or the exclusion of AD.
Resumen de: WO2024235879A1
The invention relates to a nasal fluid sample obtained from a subject comprising the marker protein(s) β amyloid (Aβ), phosphorylated Tau (pTau) and/or total Tau (tTau). The invention further relates to a nasal fluid sample comprising the marker protein(s) Aβ, pTau and/or tTau for use in a method for the aid in diagnosis of neurodegenerative diseases and the use of a nasal fluid sample comprising the marker protein(s) Aβ, pTau and/or tTau for the aid in diagnosis of a neurodegenerative disease. The invention further relates to a method for the aid in diagnosis of a neurodegenerative disease in a subject/individual.
Resumen de: WO2024227045A1
The present disclosure provides methods and kits for identifying and treating individuals at risk of or suffering from disease such as a neurological condition or disease. In general, detection or measurement of one or more biomarkers, such as neurofilament light chain (NfL), and combinations thereof with assays of the present disclosure, assists in the identification of disease such as neurological disease. The present disclosure also provides methods for selecting patients for treatment of neurological disease.
Resumen de: US2025123294A1
In one aspect, a method for screening an individual for head and neck cancer, which comprising: acquiring a saliva sample from the individual, analyzing the saliva sample to detect one or more of HPVs and at least one of a phenotypic biomarker, a regulatory biomarker, a microbiome-derived biomarker, and a metabolomic biomarker dysregulated due to HPV infection, wherein detection of both of the HPV and at least one of said biomarkers indicates the individual is at risk of head and neck cancer.
Resumen de: US2025003990A1
0000 Disclosed herein are improved assays, cartridges, kits, and methods of use thereof for detecting biomarkers, e.g., one or more biomarkers of brain injury, including, without limitation, biomarkers of acquired brain injury (ABI), such as, traumatic brain injury (TBI). The improved assays described herein may aid in the diagnosis and evaluation of a subject (e.g., a human subject) that has sustained or may have sustained an injury to the head (e.g., TBI) by detecting levels of a biomarker, such as UCH-L1, GFAP, or a combination thereof, in samples taken from a subject (e.g., a human subject).
Resumen de: CN122259816A
本发明涉及一种用于脑类器官药物测试的实时监测方法和系统，包括如下步骤：S1、进行脑类器官的制备与预培养；S2、微电极阵列芯片与反应微室的准备：将芯片安装于反应微室中，所述反应微室中央设计花瓣式流体槽结构，中心为样本腔体，外围的花瓣槽道与入口和出口流道相连；S3、脑类器官的装载与固定：在下层微电极阵列电极中心放置脑类器官后放置上层微电极阵列芯片，使脑类器官被夹持在上下电极之间，保证接触充分但不造成压伤；S4、药物灌注与电生理实时监测：将药物沿流道进入花瓣式流体槽并扩散至反应腔体，实时记录脑类器官电信号变化；S5、进行系统清洗与复用。
Resumen de: WO2025038979A1
Material compositions and/or methods useful for the prophylaxis and/or treatment of protein depletion (proteinopenia) are provided, including material compositions that retains native function of a peptide/protein while limiting and/or preventing amyloid formation and/or aggregation of said peptide/protein. Material compositions and formulations for enhancing peptide/protein solubility, stability, circulation time, receptor interaction, brain penetrance, CSF half-life, facilitating peptide/protein synthesis and purification are also provided.
Resumen de: GB2702871A
Automatically validating quality data of at least a digital slide 110, 118 scanned by an optical device. The slide is identified 122 with metadata 120 and object detection 128 locates the stained core. The data from the stained core is aligned into a standard form 132 and evaluated against a threshold 134. The stained core is compared to a control core 136 to generate the validation output 138 which is transmitted to a downstream device 140. Generating the validation output may use a stain statistical model 142 to compute the threshold value and may include cross validating 170 a positive control core 164 to confirm. Further a reliability of the validation output may be obtained. This requires configuring one or more optical device parameters comprising a magnification level and a scanning speed of the optical device as a function of the stained core of interest and the positive control core. Figure 1
Resumen de: WO2025062119A2
The invention relates to a compound of formula I, wherein: A, B, R1, R2, L1, m and n are as defined in the specification, or a salt or solvate thereof, which compounds are useful for forming Raman-tagged bioconjugates with a biomarker and/or biomolecule and are detectable with Raman spectroscopy
Resumen de: CN120142636A
The invention relates to prediction of post-stroke intestinal butyrate production microbiota and intestinal butyrate level on a post-stroke cognitive function and application of the post-stroke intestinal butyrate production microbiota and the intestinal butyrate level. Experimental research shows that the butyrate and/or the butyrate-producing flora can be used as a marker for predicting the cognitive function after the cerebral apoplexy, and the cognitive function after the cerebral apoplexy can be predicted by detecting the intestinal butyrate level after the cerebral apoplexy and/or the abundance of the butyrate-producing flora.
Resumen de: CN122249712A
本申请涉及高灵敏的免疫检测方法及系统。提供了一种高灵敏度目标蛋白的免疫检测方法，包括：捕获目标蛋白，得到含有免疫复合物的溶液；在无动力装置的作用下将含有免疫复合物的溶液平铺至检测载体；将免疫复合物固定在至少一个面上；以及检测并计算免疫复合物的浓度。本公开的免疫检测方法的使用结构简单、成本低的耗材结构，实现了高灵敏度的检测待测目标蛋白。
Resumen de: WO2024213092A1
The present invention relates to protein markers relevant to mild cognitive impairment (MCI) and Alzheimer's disease (AD), especially those detectable in blood samples. Thus, methods and compositions are provided for risk assessment and early diagnosis of MCI and AD based on the analysis of these protein markers. Further provided are methods and compositions useful for evaluating the efficacy of a therapy for MCI or AD.
Resumen de: US20260169011A1
Provided herein are methods for providing personalized nutritional supplementation to a subject. Also provided are compositions of personalized nutritional supplementation for subjects in need thereof.
Resumen de: WO2026128628A1
The present disclosure is related to non-destructive, long-term electrophysiological recording and stimulation of organoids. For example, an example device includes biocompatible material and electrodes fabricated onto the biocompatible material. The example device, through controlled buckling and microfolding, forms a pocket for an organoid.
Resumen de: US20260166125A1
Disclosed are compositions and methods for using heme and at least one PAMP and/or DAMP molecule for activating NLRP12 and/or NLRC5 and inflammatory cell death. Also provided is a screening assay for identifying NLRP12 and/or NLRC5 inhibitors and use of such inhibitors in the treating or ameliorating of NLRP12-mediated or NLRC5-mediated inflammation associated with a hemolytic disease, infectious disease, cancer, or inflammatory syndrome.
Resumen de: US20260167928A1
Disclosed herein are methods and compositions useful in screening a compound for its effect on proteotoxicity and proteinaceous inclusions involved in neurological disease.
Resumen de: WO2021048619A2
The disclosure provides immunogenic peptides, compositions, means, and methods for treating Alzheimer's disease or mild cognitive impairment. The disclosure turther provides means and methods for diagnosing patients, selecting patients for treatment, and/or evaluating the efficacy of treatment for Alzheimer's disease or mild cognitive impairment
Resumen de: US20260168979A1
0000 Embodiments of the disclosure provide a method of man-aging information related to a cannabis product across a distributed validated system. The method includes enabling an authorized user to create a plurality of data containing genetic profile of a seed, plant growth conditions of a crop, and manufacturing information used for production of the cannabis product, and measurements of quality and quantity of desired components and undesired components in the cannabis product. The method includes associating the plurality of data to a record which is identified by a unique identifier. The method includes storing the record into a memory for access by one or more of a plurality of authorized users using the unique identifier. The method includes analyzing the cannabis product to determine the quality and quantity of desired components and undesired components in the cannabis product. The method includes determining concentration of cannabinoids in the cannabis product.
Nº publicación: AU2024376969A1 18/06/2026
Solicitante:
CAMBRIDGE ENTERPRISE LTD
CAMBRIDGE ENTERPRISE LIMITED
Resumen de: AU2024376969A1
The invention relates to methods of determining whether a subject has, or is at risk of developing, a neurodegenerative disorder using ultra-sensitive techniques, in particular a single-molecular array detection method.
BOPI
Sede Electrónica
